Evidence map›Paper›PMID 40098850›Full record

ArticleAnnals of thoracic surgery short reports2025

Salvage Surgery for Thoracic SMARCA4-Deficient Undifferentiated Tumor.

Masatoshi Kanayama, Akihiro Taira, Katsuma Yoshimatsu, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Aya Nawata, Fumihiro Tanaka

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of thoracic surgery short reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. ThoracicJournal of thoracic disease · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masatoshi KanayamaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Akihiro TairaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Katsuma YoshimatsuSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hiroki MatsumiyaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masataka MoriSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masaru TakenakaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Koji KurodaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Aya NawataDepartment of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Fumihiro TanakaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) may be effectively managed with immune checkpoint inhibitors; however, the management of posttreatment exacerbations remains uncertain. A 48-year-old man underwent chemotherapy (cisplatin and pemetrexed) along with PD-L1 and CTLA-4 inhibitors, resulting in significant improvement. Subsequently, maintenance therapy was initiated but discontinued because of drug-induced pneumonia. Although prednisone treatment resolved the pneumonia, salvage surgery was performed for exacerbation of an enlarged chest tumor and lymph nodes. No additional postoperative treatment was administered, and the patient has completed 2.5 years of treatment. This case highlights the potential efficacy of salvage surgery in the management of SMARCA4-UT exacerbations.

Identifiers

PMID40098850
PMCPMC11910827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.